The Nobel Prize in Physiology or Medicine 2022 was awarded to Svante Pääbo today "for his discoveries concerning the genomes of extinct hominins and human evolution." Pääbo, who is currently the director of the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, and his colleagues overcame extreme technical challenges to sequence the DNA of ancient hominids – because after tens of thousands of years, there is no such thing as aging well for DNA. Read More
Preclinical research led by the University Hospital Würzburg in Germany shows early promise for chimeric antigen receptor (CAR) T-cell therapies to treat invasive pulmonary aspergillosis, a serious fungal infection with limited current treatment options. Read More
Antimicrobial peptides (AMPs) are a type of active peptide produced by the organism that are important host-defense factors, with broad-spectrum antibacterial properties, as well as significant properties such as antifungal and antiviral activity and immune regulation, among others. Read More
Researchers from Lantern Pharma Inc. presented preclinical data for the small-molecule DNA-damaging agent LP-284, being developed for the treatment of hematological cancers. Read More
Researchers from the University of Queensland have published preclinical data on the novel glycopeptide antibiotic MCC-5145, being developed for the treatment of gram-positive bacterial infections. Read More
Recent evidence suggests that spironolactone, a mineralocorticoid receptor antagonist, may modulate alcohol seeking and consumption, for which current therapies are limited. Read More
Immuneering Corp. has received FDA clearance of its IND application for IMM-1-104, paving the way for the company to initiate a phase I/IIa trial of this oral, once-daily small molecule in development for the treatment of advanced RAS-mutant solid tumors. Read More
Zhejiang University has disclosed transient receptor potential cation channel subfamily M member 2 (TRPM2) antagonists reported to be useful for the treatment of stroke and ischemia-reperfusion injury, among others. Read More
Medshine Discovery Inc. has identified thiophene compounds acting as lysine-specific histone demethylase 1A (LSD1) inhibitors reported to be useful for the treatment of cancer. Read More
Xuanzhu Pharma Co. Ltd. has discovered new tricyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer. Read More
Janssen Pharmaceutica NV has patented cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, rheumatoid arthritis and inflammatory disorders. Read More
